Jingwei Sun

Company: Grit Biotechnology

Job title: Vice President, Research & Development

Bio:

Dr. Jingwei Sun is the Vice President of Research and Discovery at Grit Biotechnology. She received her Ph.D. and completed her postdoctoral training in Immunobiology at Yale University, where she trained under Professor Lieping Chen. Dr. Sun has extensive experience in discovery and product development in the fields of novel immunotherapies. She is one of the co-discoverers of Siglec-15, a novel immunosuppressive molecule now targeted by antibody therapies currently in Phase II clinical trials in the U.S.

Prior to joining Grit Biotechnology, Dr. Sun led a team at Intellia Therapeutics to establish CRISPR-based in vivo screening in mouse tumor models, leading to the identification of several novel targets that enhance the function and efficacy of adoptive cell therapies in solid tumors.

At Grit Biotechnology, Dr. Sun has led the development of next-generation tumor-infiltrating lymphocyte (TIL) products. GT101 was the first TIL therapy in China to enter pivotal Phase II clinical trials, and GT201, a gene-edited TIL product, has received IND clearance in both China and the U.S. to initiate Phase I clinical studies. Dr. Sun has authored multiple peer-reviewed articles in top-tier journals such as Nature Medicine, Cell, The Journal of Clinical Investigation, and Cancer Discovery, with over 2,500 citations. She is also the inventor of more than 50 international patent applications.

Seminars:

Development of a Next-Generation Dual Knock-Out TIL Product GT300 with AaCas12bMax Nuclease 12:00 pm

GT300 is a CRISPR/AaCas12bMax engineered TIL product with KO of two key immunoregulatory targets that reverses TIL exhaustion and overcomes the harsh TME A safety assessment framework was developed aligning with FDA guidelines, incorporating orthogonal methodologies for off-target and chromosomal structural variation assessment Comparative analysis of SpCas9- versus AaCas12bMAXedited TIL products, including on-target efficiency, safety…Read more

day: Conference Day One R&D Track AM